Crystalys Therapeutics key facts
as of Oct 2026- Developer of innovative therapeutics designed to address the significant unmet medical needs of people living with gout.
- Crystalys Therapeutics is valued at approximately $263.0M as of Oct 2026 (last reported valuation).
- It has raised $205.0M; the latest was Early Stage VC ($205.0M) in Sep 2025.
- Notable investors include KB Investment, Alexandria Venture Investments, Novo Holdings, Perceptive Advisors, SR One Capital Management — 15 tracked in total.
- Status: Privately Held (backing).
Crystalys Therapeutics's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Crystalys Therapeutics: the Monday email on marks, rounds and moves
Crystalys Therapeutics funding rounds
No funding rounds for Crystalys Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Crystalys Therapeutics
15+Crystalys Therapeutics valuation
Crystalys Therapeutics's last reported valuation was $263 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Crystalys Therapeutics investors
15 investors are on record for Crystalys Therapeutics, including KB Investment, Alexandria Venture Investments, Novo Holdings and Perceptive Advisors.
About Crystalys Therapeutics
Developer of innovative therapeutics designed to address the significant unmet medical needs of people living with gout. The company offers advanced research capabilities and clinical trial development to access new treatment options that improve quality of life, enabling patients with gout to access improved therapeutic options.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2025
- Employees
- 16
- Website
- crystalystx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.